Researchers use optogenetic based deep brain stimulation to help treat motor dysfunction in animal models of Parkinson's disease. The new technique provides insights into why DBS works and ways in which it can be improved on a patient-by-patient basis.
Long term outcome data of patients with treatment-resistant depression found subcallosal cingulate deep brain stimulation (SCC DBS) was both effective at relieving symptoms and safe.
Researchers report EEG technology has the ability to study activity of areas deep inside the brain, such as the thalamus and nucleus accumbens. The findings will help shed new light on disorders that affect these brain regions, such as Parkinson's disease and OCD.
Researchers have developed a neurofeedback system which allows Parkinson's patients to voluntarily control beta wave activity in the subthalamic nucleus.
MIT researchers have developed a new sensor that is able to track and monitor dopamine in the brain for up to a year. The sensor could be a useful tool in monitoring dopamine levels in those with Parkinson's disease, depression and other conditions linked to dopamine deficiencies.
Researchers report the adverse cognitive effects associated with DBS in Parkinson's patients are linked to a different neural pathway than the one responsible for the motor effects generated by the treatment.